Why does SPRAVATO generate two separate charges?

SPRAVATO cannot be taken home. Federal REMS rules require that every dose be given in a certified setting and that you stay at least two hours afterward for monitoring of blood pressure, sedation, and dissociation. The drug is billed as a medication and the monitored stay is billed as a clinical service. They are approved separately, cost-shared separately, and assisted by separate programs. A savings program that covers one does not automatically cover the other, which is the single most common surprise patients run into.

Can I use the SPRAVATO savings card if I have Medicare or Medicaid?

No. Federal law prohibits patients with Medicare, Medicaid, TRICARE, VA coverage, or other government insurance from using manufacturer copay assistance. This is a legal restriction, not a decision by the clinic or the manufacturer. Other help may still be available to you, including the Johnson & Johnson Patient Assistance Program, which Janssen states is open to people with government coverage that does not fully meet their needs, as well as Medicare Savings Programs, Ohio Medicaid, and independent charitable foundations.

What if I do not have insurance at all?

Paying cash for SPRAVATO is expensive, and we would rather say so plainly than let you find out later. The more promising route is usually the Johnson & Johnson Patient Assistance Program, which may provide the medication at no cost for up to one year to uninsured patients who meet the income requirements. That program covers the drug only, not the monitored visit. Call us and we will walk through what applies to your situation before you commit to anything.

How long does prior authorization take?

Routine requests commonly take about one to two weeks once the documentation is complete. Under federal rules that apply to most plans, insurers must respond within 72 hours for urgent requests and within seven days for standard ones. The delay is rarely the insurer's review time. It is almost always the time spent collecting an antidepressant history with the doses and durations attached, which is why gathering that before your first appointment is the most useful thing you can do.

What happens if my prior authorization is denied?

A first denial is often procedural rather than final, and is frequently resolved by supplying a missing detail such as the dose or duration of a prior antidepressant. If it is not resolved that way, your prescriber can request a peer-to-peer review, and you have the right to an internal appeal. If the internal appeal fails, Ohio law gives you the right to an independent external review: you have 180 days from the final denial to request one, and the independent review organization must issue a written decision within 30 days, or 72 hours for an expedited review. If the reviewer rules in your favor, the plan must provide coverage.

Does my plan require me to be on an oral antidepressant?

Possibly, even though the FDA no longer requires it for treatment-resistant depression. In January 2025 the FDA approved SPRAVATO as a standalone monotherapy for TRD in addition to its existing approval for use with an oral antidepressant. Some payer policies have not been updated since that change and still ask for documentation of a concurrent oral antidepressant. We document whichever applies to you and, when a policy appears to predate the label change, we say so in the authorization request. Note that for the separate indication of major depressive disorder with acute suicidal ideation or behavior, an oral antidepressant is still required.

Will you tell me what I will owe before I start treatment?

Yes. Before anything is scheduled, our team contacts your plan to confirm whether SPRAVATO is a covered benefit, what your cost sharing looks like, whether a referral is required, and whether you qualify for manufacturer assistance. We then review the numbers with you so you can decide. A benefits check costs nothing and commits you to nothing. What we cannot do is guarantee a figure in advance, because the amount depends on your plan's own adjudication, and any clinic that promises you a precise number before running a benefits check is guessing.

SPRAVATO® · Beachwood, Ohio

SPRAVATO® Cost and Prior Authorization

Why treatment generates two separate charges instead of one, which assistance programs apply to each, what your plan wants to see before it approves, and what to do if it says no. Written for patients in Cleveland and Northeast Ohio.

Request a Benefits Check Call 216-755-4044

There is no single price for SPRAVATO, because every treatment produces two separate charges: the medication, and the monitored two-hour visit that federal rules require with every dose.

They are covered separately, cost-shared separately, and helped by separate assistance programs. Understanding that split is most of what you need to know, and it is the part that surprises people after they have already started.

If you have commercial insurance and qualify for the manufacturer's programs, your medication cost can fall to as little as $10 per treatment and your observation cost to $0 after rebate. If you have Medicare or Medicaid, federal law blocks those particular programs — but other help exists, and it is frequently overlooked.

Call (216) 755-4044 for a free benefits check. It commits you to nothing.

Why you will see two charges, not one

SPRAVATO is not a prescription you pick up and take home. Because of its risk of sedation, dissociation, and blood pressure elevation, the FDA permits it only through a restricted program called SPRAVATO REMS, which requires that every dose be self-administered in a certified healthcare setting and that you remain there for at least two hours afterward while a clinician monitors you.

That requirement is clinical, but it has a financial consequence most people do not anticipate. Your treatment is billed in two pieces.

1. The medication

The esketamine itself, dosed at 56 mg or 84 mg depending on what your prescriber orders. This is the larger of the two charges by a wide margin.

It is usually processed under your plan's medical benefit rather than your pharmacy benefit, because it is administered in a clinic. Some plans instead route it through a specialty pharmacy.

2. The monitored visit

The two-hour supervised observation period, including repeated blood pressure checks and clinical assessment before you are cleared to leave.

This is billed as a clinical service. It is smaller than the drug charge, but it recurs at every single treatment — and some assistance programs do not touch it.

Here is why this matters in practice. The manufacturer's main savings program applies to the medication and, in Janssen's own words, "does not cover the cost of treatment observation." A patient who enrolls, sees the drug cost drop to almost nothing, and assumes they are covered can still receive a bill for the observation at every visit. Janssen created a second, separate program specifically to close that gap. You have to be enrolled in both.

Charges per treatment

Two: drug + monitored visit

Monitoring required

At least 2 hours, every dose

Prior authorization

Required by nearly all plans

Benefits check

Free, before you commit

What actually determines your share

Once a plan approves SPRAVATO, approval alone does not tell you what you will pay. Four variables do most of the work:

Your deductible, and where you are in the plan year. This is the biggest single driver. The same treatment that costs you very little in November can cost a great deal in January, because the deductible resets. Patients starting in late December often face two deductibles within a few weeks.
Your coinsurance. Most plans pay a percentage rather than a flat copay for drugs administered in a clinic. A 20 percent coinsurance on an expensive medication is still a meaningful number.
Whether it runs through your medical or pharmacy benefit. These often have entirely different deductibles and different cost sharing. Some plans also require the drug to be supplied by a particular specialty pharmacy rather than purchased by the clinic.
Your out-of-pocket maximum. SPRAVATO's induction schedule is front-loaded — twice weekly for the first four weeks. Many patients reach their annual out-of-pocket maximum during induction, after which the rest of the year costs substantially less. The expense is real but it is usually front-loaded rather than evenly spread.

For patients on Medicare, SPRAVATO given in a clinic generally falls under Part B rather than Part D. In 2026 the Part B annual deductible is $283, after which Medicare typically pays 80 percent of the approved amount and you are responsible for the remaining 20 percent. A Medigap supplement or a Medicare Advantage plan changes that math, sometimes considerably.

What help exists, by coverage type

The assistance available to you depends almost entirely on what kind of insurance you have. This is the part that generic advice online gets wrong most often.

Your coverage	Manufacturer copay programs	What usually applies instead
Commercial or employer plan	Eligible	SPRAVATO withMe Savings Program for the medication, plus the Observation Rebate Program for the monitored visit. Enroll in both.
Medicare / Medicare Advantage	Prohibited by law	Part B cost sharing applies. Johnson & Johnson Patient Assistance Program, Medicare Savings Programs, and independent charitable foundations.
Ohio Medicaid / managed care	Prohibited by law	Medicaid cost sharing is minimal. Prior authorization is still required, and plan-specific criteria vary.
TRICARE or VA	Prohibited by law	Benefits are determined by the program. Johnson & Johnson Patient Assistance may apply if coverage does not fully meet your needs.
Uninsured	Not applicable	Johnson & Johnson Patient Assistance Program may provide the medication at no cost for up to a year if you meet income requirements.

If you have commercial insurance

Janssen runs two programs under the SPRAVATO withMe umbrella, and they do different jobs:

The Savings Program covers the medication. Janssen states that eligible patients pay as little as $10 per treatment, and that you can participate without sharing income information. Quantity limits and a maximum program benefit per calendar year apply.
The Observation Rebate Program covers the monitored stay, with eligible patients paying $0 after rebate for the observation portion of each treatment.

Both are run by the manufacturer, not by us, and Janssen can change or end either one without notice. You can confirm current terms and enroll directly at spravato.com or by calling SPRAVATO withMe at 1-844-479-4846. We are glad to help you through the enrollment.

One thing worth asking your employer's plan

Some employer plans use arrangements called copay accumulators or copay maximizers. Under these, the money a manufacturer program contributes on your behalf does not count toward your deductible or out-of-pocket maximum. You feel no difference while the assistance lasts, then face the full deductible once the program's annual benefit is exhausted.

If your plan uses one, it is better to know in month one than in month seven. It is a fair question to ask your benefits administrator directly, and we will flag it if we spot it during your benefits check.

If you have Medicare, Medicaid, TRICARE, or VA coverage

Federal law prohibits manufacturer copay assistance for anyone with government insurance. This is not a clinic policy or a manufacturer decision, and no provider can work around it.

What is frequently missed is that the Johnson & Johnson Patient Assistance Program is a different thing entirely, and it is not limited to the uninsured. Janssen describes it as available to people who are uninsured or who have "commercial, employer-sponsored, or government coverage that does not fully meet your needs," with eligible patients potentially receiving the medication at no cost for up to one year subject to income requirements. For a Medicare patient facing 20 percent coinsurance on an expensive drug, that program is often the most important option available — and it is the one most often assumed not to apply.

Independent charitable foundations are another route. They set their own eligibility rules, funding opens and closes unpredictably, and no one can promise they will help. But they are worth checking.

Prior authorization: what your plan wants to see

Nearly every payer requires prior authorization before your first dose. Approval is not arbitrary. Plans are checking for a specific set of documented facts, and knowing what they are makes the process considerably faster.

A documented diagnosis of treatment-resistant depression, or major depressive disorder with acute suicidal ideation or behavior
A record of at least two prior antidepressant trials — the medication names, the doses, how long you took each one, and why each was stopped
Evidence those trials were of adequate dose and duration, typically six to eight weeks at a therapeutic dose
A recent standardized depression score, such as a PHQ-9 or MADRS
Confirmation of whether SPRAVATO will be used on its own or alongside an oral antidepressant
Documentation that treatment will occur in a REMS-certified setting with the required two-hour monitoring

Our administrative team assembles and submits all of this. The single most useful thing you can do is arrive with your antidepressant history already written down, including doses and approximate dates. Incomplete medication history delays more authorizations than every other cause combined — not because insurers are obstructive, but because "tried Zoloft, didn't work" is not something a reviewer can approve against.

The oral antidepressant question

This one is genuinely confusing right now, and a lot of what is written online is out of date.

In January 2025 the FDA approved SPRAVATO as a standalone monotherapy for treatment-resistant depression, in addition to its original approval for use alongside an oral antidepressant. Both are now on-label, and the choice belongs to your prescriber.

Payer policies, however, do not update the moment a label changes. Some plans still have criteria written before that approval and continue to ask for documentation of a concurrent oral antidepressant. The manufacturer publishes a resource specifically on navigating access to SPRAVATO as monotherapy, which tells you how common the friction is. We document whichever approach your prescriber has chosen, and where a policy appears to predate the label change, we say so directly in the authorization request.

One exception worth knowing: for the separate indication of major depressive disorder with acute suicidal ideation or behavior, an oral antidepressant is still required by the label.

How long approval takes

Once documentation is complete, routine requests commonly resolve in about one to two weeks. Federal rules applicable to most plans require insurers to respond within 72 hours for urgent requests and seven days for standard requests, though the clock only starts when they have what they asked for.

Realistically, the collection of records is the slow part, not the insurer's review. If your prior antidepressant trials were managed by a prescriber you no longer see, request those records early.

If your plan says no

A first denial is often procedural rather than final. The most common reasons are a missing dose or duration on a prior medication, a depression score that is too old, or a policy criterion that was not addressed explicitly. Many are resolved by supplying one piece of information.

If that does not work, you have escalating rights, and in Ohio they are stronger than most people realize.

Peer-to-peer review. Your prescriber speaks directly with a physician reviewer at the plan. This is frequently the fastest path and resolves a meaningful share of denials without a formal appeal.
Internal appeal. A formal request that the plan reconsider, usually supported by a letter of medical necessity documenting your treatment history and why the alternatives are inadequate. Under Ohio law, if the plan does not issue a written decision within 30 days, you may treat the internal process as exhausted and move on.
External review. If the internal appeal fails, Ohio law gives you the right to review by an independent review organization that does not work for your insurer. You have 180 days from the final denial to request one. The reviewer must issue a written decision within 30 days, or within 72 hours for an expedited review. If the reviewer rules in your favor, your plan is required to provide coverage.

That external review right comes from Ohio Revised Code Chapter 3922 and applies regardless of how much the treatment costs. The Ohio Department of Insurance can help if a plan refuses to process a request properly. We handle appeals for our patients as part of the authorization process.

Questions worth asking before you start anywhere

These apply to any SPRAVATO provider, including us:

Will you bill my insurance directly, or am I paying you and seeking reimbursement myself?
Is the two-hour observation billed separately from the medication, and what is my cost for each?
Will you help me enroll in both manufacturer programs, or only the medication one?
What happens financially if I miss a scheduled dose, or if my authorization lapses mid-course?
If my plan denies it, do you handle the appeal, or is that on me?

A provider who cannot answer the second question clearly has not thought carefully about what their patients actually pay.

What we do before you commit

Call us or send a request online. Tell us your insurance carrier and member ID. There is no charge and no obligation.
We verify your benefits. Our team contacts your plan directly to confirm whether SPRAVATO is a covered benefit, what your cost sharing looks like, whether a referral is required, whether the drug runs through your medical or pharmacy benefit, and whether you qualify for manufacturer assistance.
We go over the numbers with you. We review what we found and what you can expect to owe, before anything is scheduled. If the treatment does not make sense for you financially or clinically, we will tell you.
We handle the prior authorization. If you decide to move forward, our staff assembles the documentation, submits the request, tracks it, and manages any appeal.

No clinic can promise coverage in advance

Be cautious with any provider who guarantees your insurance will pay before running a benefits check, or who quotes you an exact out-of-pocket figure sight unseen. Coverage depends on your specific policy, your documented diagnosis, your treatment history, and how your plan adjudicates the claim. What we can promise is that we will find out and tell you what we learn before you owe anything.

Common questions

How much does SPRAVATO cost?

There is no single price, because treatment produces two charges: the medication and the required two-hour monitored visit. What you pay depends on your deductible, your coinsurance, where you are in your plan year, and which assistance programs you qualify for. Commercially insured patients who qualify for the manufacturer's programs may pay as little as $10 per treatment for the medication and nothing for the observation.

Why are there two separate charges?

SPRAVATO cannot be taken home. REMS rules require every dose be given in a certified setting with at least two hours of monitoring afterward. The drug is billed as a medication and the monitored stay as a clinical service — approved separately, cost-shared separately, and assisted by separate programs. A program covering one does not automatically cover the other.

What is the SPRAVATO withMe Savings Program?

A manufacturer copay program for patients with commercial or private insurance. Janssen states eligible patients pay as little as $10 per treatment for the medication, with no income disclosure required, subject to quantity limits and an annual maximum benefit. It does not cover observation — a separate Observation Rebate Program does that, at $0 after rebate. Terms are set by Janssen and can change. Confirm at spravato.com or 1-844-479-4846.

Can I use the savings card with Medicare or Medicaid?

No. Federal law prohibits patients with Medicare, Medicaid, TRICARE, VA, or other government coverage from using manufacturer copay assistance. No provider can work around this. Other help may still apply, including the Johnson & Johnson Patient Assistance Program, Medicare Savings Programs, and independent foundations.

What if I am uninsured?

Paying cash is expensive and we would rather say so plainly. The more promising route is usually the Johnson & Johnson Patient Assistance Program, which may provide the medication at no cost for up to a year if you meet income requirements. It covers the drug, not the monitored visit. Call us and we will walk through what applies before you commit to anything.

Does SPRAVATO require prior authorization?

Nearly always — commercial, Medicare Advantage, and Ohio Medicaid managed care plans all typically require it before the first dose. Plans want a TRD diagnosis, at least two documented antidepressant failures with doses and durations, a recent PHQ-9 or MADRS, and confirmation of REMS-certified administration. We assemble and submit it for you.

How long does approval take?

Commonly one to two weeks once documentation is complete. Federal rules require most plans to respond within 72 hours for urgent and seven days for standard requests. The delay is usually collecting your antidepressant history with doses attached, not the insurer's review — which is why writing it down before your first visit genuinely speeds things up.

What if I am denied?

First denials are often procedural and resolved by supplying a missing detail. Beyond that: a peer-to-peer review between your prescriber and the plan's reviewer, then a formal internal appeal, then external review. Ohio law gives you 180 days from a final denial to request an independent external review, with a written decision due in 30 days (72 hours if expedited). A reversal is binding on your plan. We handle appeals for our patients.

Do I have to take an oral antidepressant too?

Not under the FDA label — since January 2025 SPRAVATO has been approved as monotherapy for TRD as well as in combination. But some payer policies predate that change and still ask for a concurrent oral antidepressant. We document whichever applies to you. For the separate indication of depression with acute suicidal ideation, an oral antidepressant is still required.

Will you tell me what I owe before I start?

Yes. We verify your benefits and review the numbers with you before anything is scheduled. A benefits check is free and commits you to nothing. What we will not do is guarantee an exact figure in advance — that depends on your plan's own adjudication, and anyone quoting you a precise number before checking is guessing.

Serving Northeast Ohio Communities

CarePoint Infusion Center is in Beachwood just off I-271, roughly 20 minutes from downtown Cleveland. Because SPRAVATO requires a two-hour monitored stay twice a week during the first month — and you cannot drive yourself home afterward — a shorter drive makes the schedule far more realistic to sustain.

We conveniently serve patients from:

Cleveland Beachwood Hudson Medina Solon Westlake Lakewood Elyria Lorain Parma Strongsville Brecksville Twinsburg Shaker Heights University Heights Lyndhurst South Euclid Mayfield Heights Warrensville Heights Orange Village Pepper Pike Chagrin Falls Akron Fairlawn Cuyahoga Falls Stow Kent Tallmadge Barberton Green Canton Youngstown

And throughout Cuyahoga County and Northeast Ohio. Call (216) 755-4044 to ask about treatment in Beachwood.

Getting started

If you want to know what SPRAVATO would actually cost you, the fastest answer comes from a benefits check rather than from anything written on a website. Call (216) 755-4044 or send us a message with your insurance information, and we will find out and tell you what we learn.

CarePoint Infusion Center
23215 Commerce Park, Suite 318, Beachwood, OH 44122
Phone (216) 755-4044 · Fax 330-967-0571 · [email protected]
Monday–Thursday 8:00 AM–5:00 PM, Friday 8:00 AM–12:00 PM

If you are in crisis, do not wait for an appointment. Call or text 988, or call 911.

SPRAVATO® (esketamine) nasal spray — the treatment itself, in detail
Ketamine therapy that takes insurance — how SPRAVATO and IV ketamine differ on coverage
Prior authorization for infusion therapy — how the approval process works across all our services
Treatment-resistant depression — what the diagnosis means and what options exist
SPRAVATO® treatment near Cleveland — location, travel, and the visit schedule
Patient information — forms, billing, and appointment logistics

About the figures on this page. Drug pricing, insurance policies, and manufacturer program terms change frequently, sometimes quarterly. The amounts described here reflect Janssen's published SPRAVATO withMe program terms and the Centers for Medicare & Medicaid Services' published 2026 Medicare Part B amounts as of September 2026. Manufacturer programs are administered by Janssen Pharmaceuticals, not by CarePoint Infusion Center, and Janssen may change or end them without notice; eligibility, quantity limits, and annual maximums are set by the manufacturer. Always confirm current terms directly with SPRAVATO withMe at 1-844-479-4846 or with our office before relying on them.

Medical and financial disclaimer. This page is general education, not medical advice, financial advice, or a guarantee of insurance coverage, benefits, or cost. No estimate we provide is a contract, and your final responsibility is determined by your health plan's adjudication of the claim. SPRAVATO carries an FDA boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors, and is available only through the SPRAVATO REMS program. It is a prescription treatment requiring a physician order and is not appropriate for everyone. CarePoint Infusion Center does not provide emergency psychiatric services, crisis care, or psychotherapy. If you are having thoughts of harming yourself, call or text 988, call 911, or go to the nearest emergency department.

SPRAVATO® and SPRAVATO withMe® are registered trademarks of Janssen Pharmaceuticals, Inc. CarePoint Infusion Center is an independent provider and is not affiliated with, sponsored by, or endorsed by Janssen Pharmaceuticals or Johnson & Johnson.